Authors

EYLEA’s unique MoA: What is the rationale for the higher molar dose?

A-memia? Anecdotal evidence in the era of memes

Ian C. Han, MD, shares his thoughts on the value of anecdotal evidence in our winter 2024 editorial.

Advancements in ocular drug delivery

Options empower patients and providers to decrease treatment burden

Genetic Retinoblastoma Risk Stratified by Age Among Patients with Metachronous Bilateral Conversion

Study shows RB1-positive infants diagnosed before 9 months face higher fellow-eye retinoblastoma risk, guiding smarter surveillance and de-escalation.

EYLEA 8mg in focus: Key learnings from the pivotal trials

Real World insights with EYLEA 8mg

Propelling R&D for Novel Retinal Therapies Through Innovative Clinical Trial Design

A field guide to optic disc drusen

Clinical associations, imaging strategies and establishing a differential diagnosis from pseudopapilledema.

Q&A: Evolving approaches to geographic atrophy management

David S. Boyer, MD, outlines changes in GA evaluation, the role of complement inhibition, monitoring for neovascular conversion, and emerging therapies.

Foundation Fighting Blindness releases 4-year RUSH2A data to public

RUSH2A is an ongoing natural history study for patients with mutations in the USH2A gene causing Usher syndrome type 2A or nonsyndromic retinitis pigmentosa (RP).

Regeneron receives another CRL for its Eylea 8 mg

Regeneron faces another FDA setback for Eylea HD due to manufacturing issues, but plans for new facilities signal future production improvements.

Boehringer Ingelheim launches two Phase 2 clinical trials for its geographic atrophy treatment candidates

Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.

AI-powered Eye2Gene uses multimodal imaging to diagnose inherited retinal disease

The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests.

Wet AMD therapeutics: Technologies raising the ceiling for functional visual outcomes

Neovascular macular degeneration is multifactorial, which requires future agents to target multiple pathways.

FDA expands faricimab label to include treatment of macular edema secondary to retinal vein occlusion beyond 6 months

OSN New York Retina 2024: Understanding how next-generation anti-VEGFs perform in real-world settings compared to trials

Ferhina S. Ali, MD, discussed the real-world efficacy and durability of next-generation anti-VEGF agents like faricimab and aflibercept 8 mg, emphasizing how large-scale data offers insights into their performance and safety beyond clinical trials.

Getting to the root of geographic atrophy: Diagnosis and management

Three real-world GA cases reveal why early imaging-guided treatment matters, how fast vision can decline, and how to manage CNV risk with anti-VEGF.

Ophthalmic drug shortages more frequent, longer lasting than average

US eye medication shortages make up a sizable share of active drug shortages and last longer, driven by manufacturing issues, weak generics and unclear causes.

FLORetina: Inadvertent anti-VEGF interval increases during the COVID-19 pandemic

The pandemic reshapes treatment intervals for neovascular AMD, revealing flexible strategies that maintain visual outcomes and enhance patient care.